Pair your accounts.

Export articles to Mendeley

Get article recommendations from ACS based on references in your Mendeley library.

Pair your accounts.

Export articles to Mendeley

Get article recommendations from ACS based on references in your Mendeley library.

You’ve supercharged your research process with ACS and Mendeley!

STEP 1:
Click to create an ACS ID

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

MENDELEY PAIRING EXPIRED
Your Mendeley pairing has expired. Please reconnect
ACS Publications. Most Trusted. Most Cited. Most Read
My Activity
CONTENT TYPES

Design, Synthesis, and Biological Evaluation of Novel Type I1/2 p38α MAP Kinase Inhibitors with Excellent Selectivity, High Potency, and Prolonged Target Residence Time by Interfering with the R-Spine

View Author Information
Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmaceutical Sciences, Eberhard-Karls-Universitaet Tuebingen, Auf der Morgenstelle 8, 72076 Tuebingen, Germany
Faculty of Chemistry and Chemical Biology, Technische Universitaet Dortmund, Otto-Hahn-Strasse 4a, 44227 Dortmund, Germany
§ Netherlands Translational Research Center B.V. (NTRC), Pivot Park, RE1210, Molenstraat 110, 5342 CC Oss, The Netherlands
*Phone: +49 7071 2972459. E-mail: [email protected]
Cite this: J. Med. Chem. 2017, 60, 19, 8027–8054
Publication Date (Web):August 23, 2017
https://doi.org/10.1021/acs.jmedchem.7b00745
Copyright © 2017 American Chemical Society

    Article Views

    3333

    Altmetric

    -

    Citations

    LEARN ABOUT THESE METRICS
    Other access options
    Supporting Info (2)»

    Abstract

    Abstract Image

    We recently reported 1a (skepinone-L) as a type I p38α MAP kinase inhibitor with high potency and excellent selectivity in vitro and in vivo. However, as a type I inhibitor, it is entirely ATP-competitive and shows just a moderate residence time. Thus, the scope was to develop a new class of advanced compounds maintaining the structural binding features of skepinone-L scaffold like inducing a glycine flip at the hinge region and occupying both hydrophobic regions I and II. Extending this scaffold with suitable residues resulted in an interference with the kinase’s R-Spine. By synthesizing 69 compounds, we could significantly prolong the target residence time with one example to 3663 s, along with an excellent selectivity score of 0.006 and an outstanding potency of 1.0 nM. This new binding mode was validated by cocrystallization, showing all binding interactions typifying type I1/2 binding. Moreover, microsomal studies showed convenient metabolic stability of the most potent, herein reported representatives.

    Read this article

    To access this article, please review the available access options below.

    Get instant access

    Purchase Access

    Read this article for 48 hours. Check out below using your ACS ID or as a guest.

    Recommended

    Access through Your Institution

    You may have access to this article through your institution.

    Your institution does not have access to this content. You can change your affiliated institution below.

    Supporting Information

    ARTICLE SECTIONS
    Jump To

    The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.jmedchem.7b00745.

    • SMILES and some data (CSV)

    • Experimental and analytical data, including HPLC purity, (HR)MS, and NMR data of compounds 260; additional characterization of binding kinetics; all general methods; experimental section for materials and intermediates; X-ray crystallography; metabolic stability determination in vitro (PDF)

    Accession Codes

    Cocrystal structures of the human p38α MAP kinase in complex with 6j and 8m, respectively, are deposited under the accession codes 5MTY and 5MTX in the Protein Data Bank. Authors will release the atomic coordinates and experimental data upon article publication.

    Terms & Conditions

    Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: http://pubs.acs.org/page/copyright/permissions.html.

    Cited By

    This article is cited by 22 publications.

    1. Wei Liu, Jingsheng Jiang, Yating Lin, Qidong You, Lei Wang. Insight into Thermodynamic and Kinetic Profiles in Small-Molecule Optimization. Journal of Medicinal Chemistry 2022, 65 (16) , 10809-10847. https://doi.org/10.1021/acs.jmedchem.2c00682
    2. Niklas M. Tormählen, Mariella Martorelli, Annette Kuhn, Florian Maier, Jamil Guezguez, Michael Burnet, Wolfgang Albrecht, Stefan A. Laufer, Pierre Koch. Design and Synthesis of Highly Selective Brain Penetrant p38α Mitogen-Activated Protein Kinase Inhibitors. Journal of Medicinal Chemistry 2022, 65 (2) , 1225-1242. https://doi.org/10.1021/acs.jmedchem.0c01773
    3. Carmen Carrillo García, Cora Becker, Michael Forster, Stefan Lohmann, Patricia Freitag, Stefan Laufer, Sonja Sievers, Bernd K. Fleischmann, Michael Hesse, Dennis Schade. High-Throughput Screening Platform in Postnatal Heart Cells and Chemical Probe Toolbox to Assess Cardiomyocyte Proliferation. Journal of Medicinal Chemistry 2022, 65 (2) , 1505-1524. https://doi.org/10.1021/acs.jmedchem.1c01173
    4. Júlia G. B. Pedreira, Philipp Nahidino, Mark Kudolo, Tatu Pantsar, Benedict-Tilman Berger, Michael Forster, Stefan Knapp, Stefan Laufer, Eliezer J. Barreiro. Bioisosteric Replacement of Arylamide-Linked Spine Residues with N-Acylhydrazones and Selenophenes as a Design Strategy to Novel Dibenzosuberone Derivatives as Type I 1/2 p38α MAP Kinase Inhibitors. Journal of Medicinal Chemistry 2020, 63 (13) , 7347-7354. https://doi.org/10.1021/acs.jmedchem.0c00508
    5. Xiaotian Kong, Peichen Pan, Huiyong Sun, Hongguang Xia, Xuwen Wang, Youyong Li, Tingjun Hou. Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK). Journal of Medicinal Chemistry 2019, 62 (24) , 10927-10954. https://doi.org/10.1021/acs.jmedchem.9b00446
    6. Wanli You, Zhiye Tang, Chia-en A. Chang. Potential Mean Force from Umbrella Sampling Simulations: What Can We Learn and What Is Missed?. Journal of Chemical Theory and Computation 2019, 15 (4) , 2433-2443. https://doi.org/10.1021/acs.jctc.8b01142
    7. Marian C. Bryan, Naomi S. Rajapaksa. Kinase Inhibitors for the Treatment of Immunological Disorders: Recent Advances. Journal of Medicinal Chemistry 2018, 61 (20) , 9030-9058. https://doi.org/10.1021/acs.jmedchem.8b00667
    8. Haoyue Xiang, Qing-Lan Zhao, Peng-Ju Xia, Jun-An Xiao, Zhi-Peng Ye, Xiong Xie, Huan Sheng, Xiao-Qing Chen, and Hua Yang . Visible-Light-Induced External Radical-Triggered Annulation To Access CF2-Containing Benzoxepine Derivatives. Organic Letters 2018, 20 (5) , 1363-1366. https://doi.org/10.1021/acs.orglett.8b00131
    9. Karoline B. Waitman, Larissa C. de Almeida, Marina C. Primi, Jorge A.E.G. Carlos, Claudia Ruiz, Thales Kronenberger, Stefan Laufer, Marcia Ines Goettert, Antti Poso, Sandra V. Vassiliades, Vinícius A.M. de Souza, Mônica F.Z. J. Toledo, Neuza M.A. Hassimotto, Michael D. Cameron, Thomas D. Bannister, Letícia V. Costa-Lotufo, João A. Machado-Neto, Maurício T. Tavares, Roberto Parise-Filho. HDAC specificity and kinase off-targeting by purine-benzohydroxamate anti-hematological tumor agents. European Journal of Medicinal Chemistry 2024, 263 , 115935. https://doi.org/10.1016/j.ejmech.2023.115935
    10. Sayantan Pradhan, Samrat Hore, Stabak Roy, Simi Manna, Paulami Dam, Rittick Mondal, Amit Ghati, Trishanjan Biswas, Subhajit Shaw, Supriya Sharma, Waikhom Somraj Singh, Suman Kumar Maji, Sankarsan Roy, Aparajita Basu, Kailash C. Pandey, Soumadri Samanta, Kapil Vashisht, Tuphan Kanti Dolai, Pratip Kumar Kundu, Saptarshi Mitra, Debasish Biswas, Abdul Sadat, Masuma Shokriyan, Amit Bikram Maity, Amit Kumar Mandal, İkbal Agah İnce. Geo-environmental factors and the effectiveness of mulberry leaf extract in managing malaria. Scientific Reports 2023, 13 (1) https://doi.org/10.1038/s41598-023-41668-3
    11. Parteek Prasher, Mousmee Sharma, Yinghan Chan, Sachin Kumar Singh, Krishnan Anand, Harish Dureja, Niraj Kumar Jha, Gaurav Gupta, Flavia Zacconi, Dinesh K. Chellappan, Kamal Dua. Recent Trends in Rationally Designed Molecules as Kinase Inhibitors. Current Medicinal Chemistry 2023, 30 (13) , 1529-1567. https://doi.org/10.2174/0929867328666211111161811
    12. Tatu Pantsar, Philipp D. Kaiser, Mark Kudolo, Michael Forster, Ulrich Rothbauer, Stefan A. Laufer. Decisive role of water and protein dynamics in residence time of p38α MAP kinase inhibitors. Nature Communications 2022, 13 (1) https://doi.org/10.1038/s41467-022-28164-4
    13. William A. Denny. Inhibitors and Activators of the p38 Mitogen-Activated MAP Kinase (MAPK) Family as Drugs to Treat Cancer and Inflammation. Current Cancer Drug Targets 2022, 22 (3) , 209-220. https://doi.org/10.2174/1568009622666220215142837
    14. Thamires R. Machado, Thayná R. Machado, Pedro G. Pascutti. The p38 MAPK Inhibitors and Their Role in Inflammatory Diseases. ChemistrySelect 2021, 6 (23) , 5729-5742. https://doi.org/10.1002/slct.202100406
    15. Débora Bublitz Anton, Rodrigo Gay Ducati, Luís Fernando Saraiva Macedo Timmers, Stefan Laufer, Márcia Inês Goettert. A Special View of What Was Almost Forgotten: p38δ MAPK. Cancers 2021, 13 (9) , 2077. https://doi.org/10.3390/cancers13092077
    16. Moustafa M. Madkour, Hanan S. Anbar, Mohammed I. El-Gamal. Current status and future prospects of p38α/MAPK14 kinase and its inhibitors. European Journal of Medicinal Chemistry 2021, 213 , 113216. https://doi.org/10.1016/j.ejmech.2021.113216
    17. Vanessa Haller, Philipp Nahidino, Michael Forster, Stefan A. Laufer. An updated patent review of p38 MAP kinase inhibitors (2014-2019). Expert Opinion on Therapeutic Patents 2020, 30 (6) , 453-466. https://doi.org/10.1080/13543776.2020.1749263
    18. Antti Poso. Molecular Modeling of Protein Kinases: Current Status and Challenges. 2020, 25-41. https://doi.org/10.1007/7355_2020_106
    19. Ireoluwa Yinka Joel, Temidayo Olamide Adigun, Olukayode Olusola Bankole, Mohammed Aminu Iduze, Tamonokorite AbelJack-Soala, Onyedika Gabriel ANI, Elijah Oluwafunto Olapade, Friday Micheal Dada, Olusola Mercy Adetiwa, Bankole Emmanuel Ofeniforo, Funmilola Olamide Akanni. Insights into features and lead optimization of novel type 1½ inhibitors of p38α mitogen-activated protein kinase using QSAR, quantum mechanics, bioisostere replacement and ADMET studies. Results in Chemistry 2020, 2 , 100044. https://doi.org/10.1016/j.rechem.2020.100044
    20. Takayoshi Kinoshita. Protein Allostery in Rational Drug Design. 2019, 45-64. https://doi.org/10.1007/978-981-13-8719-7_3
    21. Hao Lu, James N Iuliano, Peter J Tonge. Structure–kinetic relationships that control the residence time of drug–target complexes: insights from molecular structure and dynamics. Current Opinion in Chemical Biology 2018, 44 , 101-109. https://doi.org/10.1016/j.cbpa.2018.06.002
    22. Adam G. Meyer, Alex C. Bissember, Christopher J.T. Hyland, Charlotte C. Williams, Monika Szabo, Steven-Alan G. Abel, Melissa J. Bird, Isabel K. Hyland, Hoang Pham. Seven-Membered Rings. 2018, 493-550. https://doi.org/10.1016/B978-0-08-102788-2.00016-7